Novartis signs licensing deal with China's Abogen worth up to $7.8 billion
Swiss pharmaceutical company Novartis agreed to pay $575 million upfront for global rights to an autoimmune mRNA therapy developed by Chinese biotech Abogen Biosciences, with total potential payments reaching $7.8 billion.
Deal structure and licensing terms
Swiss pharmaceutical company Novartis entered a licensing and option agreement with Chinese biotechnology firm Abogen Biosciences valued at up to $7.8 billion on 2 October 2026. Under the terms of the contract, Novartis will pay $575 million upfront (equivalent to 480 million Swiss francs) to secure exclusive worldwide development and commercialization rights to lead candidate ABO2203. Abogen is eligible to receive up to $7.2 billion in additional milestone payments if Novartis exercises options for further drug programs and achieves designated clinical development, regulatory approval, and commercial revenue targets. The contract also guarantees Abogen tiered royalties on future global sales of approved products derived from the collaboration.
- Upfront payment
- 0.575 $B
- Potential milestone payments
- 7.2 $B
- Total potential value
- 7.8 $B
mRNA technology and autoimmune mechanisms
The agreement centers on ABO2203, an investigational candidate currently in clinical development for the treatment of autoimmune diseases. Autoimmune conditions occur when the immune system mistakenly attacks and damages the body's own healthy tissues, cells, and organs. ABO2203 utilizes messenger RNA technology to prompt the patient's own body to produce a therapeutic molecule directly. According to Abogen, the candidate functions as an mRNA-encoded T-cell engager designed to reset the immune system by selectively identifying and eliminating specific cell populations, including B cells that drive autoimmune pathology. The application adapts messenger RNA technology, which was studied for decades in oncology research before being used in COVID-19 vaccines developed by Moderna in the United States and BioNTech in Germany, to autoimmune disorders.
Western pharmaceutical investment in Chinese biotech
The transaction aligns with an ongoing pattern of international pharmaceutical companies turning to Chinese biotechnology developers to expand and diversify their pipelines ahead of patent expirations on existing blockbuster drugs. In recent days, Danish drugmaker Novo Nordisk secured rights to an oral obesity therapy developed by Jiangsu Hengrui Pharmaceutical in a deal valued at up to $2.6 billion, while British-Swedish company AstraZeneca committed $2 billion to Summit Therapeutics for joint oncology treatment development. Abogen has raised more than $1 billion in total private funding from global and regional investment firms, including SoftBank, 5Y Capital, Mirae Asset Management, Lilly Asia Ventures, Loyal Valley Capital, Hillhouse, PICC Capital, Qiming Ventures, and SDIC Venture Capital. Axios healthcare reporter Caitlin Owens addressed the evolution of China's pharmaceutical industry.
China has gotten really good at making new drugs, a huge government-designed shift from its history as a supplier of pharmaceutical ingredients and generics.
- Novartis / Abogen Biosciences
- 7.8 $B
- Novo Nordisk / Jiangsu Hengrui
- 2.6 $B
- AstraZeneca / Summit Therapeutics
- 2 $B
Market response and pipeline outlook
Following the announcement on Friday, Novartis shares closed down 1.4% on the Zurich stock exchange. The transaction broadens the Swiss company's portfolio of RNA-based therapeutics while providing exclusive multi-year options to in-license additional next-generation drug candidates developed on Abogen's mRNA platform. Novartis will manage global clinical advancement, regulatory filings, and commercial distribution for any partnered programs, while Abogen receives substantial capital to support its research operations alongside future milestone and royalty streams.
